Market Overview

CANbridge Life Sciences Appoints Chief Medical Officer


CANbridge Life Sciences, a biopharmaceutical company developing Western
drug candidates in China and North Asia, announced that it strengthened
the executive management team with the appointment of May Orfali, MD, as
Chief Medical Officer, on July 23, 2018. Dr. Orfali replaced Dr. Mark
Goldberg, who was acting as interim Chief Medical Officer. She is based
in Cambridge, MA.

This press release features multimedia. View the full release here:

May Orfali, MD (Photo: Business Wire)

May Orfali, MD (Photo: Business Wire)

Dr. Orfali has a deep and extensive background in clinical drug
development programs that spans two decades in multiple therapeutic
areas, with a focus on rare diseases, oncology, hematology, infectious
disease and women's health. Most recently, she was Executive Director,
Global Product Development, Pfizer, Inc., USA, where she was responsible
for patient-focused drug development across multiple rare disease assets
in hematology, sickle cell disease, hemophilia, endocrinology, gene
therapy and TTR-amyloidosis. Prior to that role, Dr. Orfali was Senior
Director and Global Medical Lead/Medicines Development Group, Specialty
Care Business Unit, Pfizer, where she was responsible for developing
rare disease drug development strategy, including gene therapy; oversaw
global drug development in TTR-amyloidosis, and was Global Medical Lead
for hematology, specifically in hemophilia A and B, across North
America, Europe and Asia, including Japan and China. Prior to her time
at Pfizer, Dr. Orfali held several clinical leadership positions,
including Senior Director, Global Medical Monitor, Oncology at Wyeth
Pharmaceutical Company, USA; VP Clinical Development and Medical Affairs
at Artisan Pharma, Inc., USA; Vice President, Clinical Research and
Medical Affairs, Aeris Therapeutics, USA; Medical Director, CDMA, Cubist
Pharmaceuticals and Medical Director, Women's Health Group at Boston
Scientific Corporation.

Dr. Orfali holds a medical degree from the University of Baghdad,
Baghdad, Iraq, and a Pharmaceutical Masters of Business Administration
from Cambridge University, Cambridge, England. She was a practicing
physician, specialized in CNS Oncology Clinical Research at Dana-Farber
Cancer Institute, in Boston, MA and completed her Fellowship in
Pediatric Oncology/Hematology at Massachusetts General Hospital and
Children's Hospital, Boston, MA.

"We are delighted that Dr. Orfali has chosen to join CANbridge as we
become a fully-commercial biopharmaceutical company with a robust
clinical trial program and pipeline," said James Xue, PhD, Chairman and
CEO, CANbridge Life Sciences. "Her broad international experience, and
proven track record of clinical trial success in multiple indications,
will be key as CANbridge continues to advance our world-class programs
in oncology and orphan-designated diseases, particularly in those that
are severely underserved in China and Asia. We would also like to thank
Dr. Mark Goldberg for serving as our interim Chief Medical Officer. He's
played an instrumental role in CANbridge's current success and will
continue to work with us in an advisory capacity."

About CANbridge Life Sciences

CANbridge Life Sciences, Ltd. is a clinical-stage bio-pharmaceutical
company accelerating development and commercialization of specialty
healthcare products for serious and critical medical conditions in China
and North Asia (Korea and Taiwan). CANbridge develops partnerships with
Western bio-pharmaceutical companies with clinical-stage pharmaceutical,
medical device or diagnostic products that are either unavailable in
China/North Asia, or address medical needs that are underserved in the
region. CANbridge also licenses, or obtains exclusive rights to
commercialize, drug and device products that are approved in their home
markets for commercialization in China and North Asia.

CANbridge has exclusive rights to develop and commercialize Puma
Biotechnology's NERLYNX® (neratinib) in China, Taiwan, Hong Kong and
Macao (collectively, greater China), which was approved by the FDA, in
2017, for the extended adjuvant treatment of adult patients with
early-stage HER2-positive breast cancer following adjuvant
trastuzumab-based therapy, and which CANbridge is developing as CAN030.
CANbridge plans to target HER2-positive cancers, including breast and
gastric. CANbridge has a license with Apogenix to develop, manufacture
and commercialize immune-oncology therapy, APG101, which CANbridge is
developing as CAN008, for the treatment of glioblastoma multiforme (GBM)
in greater China. CANbridge received China National Drug Administration
(CNDA) approval to commence a Phase II/III Trial in GBM in mainland
China, which it expects to initiate later this year. CANbridge has a
world-wide license (ex-North America) to develop, manufacture and
commercialize AVEO Oncology's clinical-stage ErbB3 (HER3) inhibitory
antibody candidate AV203, which it will develop as CAN017. CANbridge
also has an agreement with EUSA Pharma to commercialize Caphosol® in
China for the prevention and treatment of oral mucositis caused by
cancer treatments. Caphosol was approved for commercialization by the

Led and backed by a highly-seasoned executive team, with extensive
Chinese drug development experience, CANbridge has the capability to
select, acquire, develop and commercialize future therapeutics and
diagnostics targeting the unmet medical needs of Chinese and East Asian
patients with serious or critical conditions.

CANbridge is privately-held and headquartered in Beijing, China. For
more on CANbridge Life Sciences, please go to

View Comments and Join the Discussion!